Navigation Links
Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
Date:11/8/2012

CRANBURY, N.J., Nov. 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).

The data demonstrate that women taking bremelanotide showed statistically significant increases in the number of Satisfying Sexual Events (SSEs) and also showed statistically significant improved measures of overall sexual functioning and distress related to sexual dysfunction, compared with placebo.

The primary endpoint data analysis of 327 pre-menopausal women with female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or a combination of both disorders, the most common types of FSD, shows a clinically meaningful and statistically significant improvement (p=0.018) in the number of SSEs in women taking bremelanotide doses (mean change from 1.6 at baseline increasing to 2.4; pooled 1.25 mg and 1.75 mg doses) versus placebo (mean change from 1.7 at baseline increasing to 1.9) over the study period, resulting in a 50% increase in SSEs with bremelanotide versus 12% with placebo.

"We are extremely pleased to report the successful completion of this trial, which achieved statistical significance in our primary endpoint and key secondary endpoints using independently developed and validated measurement tools. Importantly, we met the objectives of the trial which demonstrated excellent safety and efficacy of the drug and identified doses for advancement into Phase 3 trials and activities" stated Carl Spana, Ph.D., President and CEO of Palatin. "Our next steps are to continue to compile and analyze additional data, to start the preparation process for an end-of-Phase 2 meeting with the FDA, and to further our discussions with potential colla
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Md. , March 3, 2015  RegeneRx Biopharmaceuticals, ... editorial in the scientific journal, Expert Opinion on ... his colleague, Dr. Zhenggang Zhang , at the ... reported that Thymosin beta 4 (TB4) has the ... remodeling 24 hours or more post-injury, leading to neurological ...
(Date:3/3/2015)... Kindred Biosciences, Inc. (NASDAQ: KIN ), ... of pets, announced today that it will release its fourth ... after the market close. The Company will host a conference ... Interested parties may access the call by dialing toll-free ... using conference ID 98449349.  The call will ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Personalized Medicine ... offering. , The aim of ... the right drug to the right patient and, ... treatment for a patient according to his/her genotype. ...
(Date:3/3/2015)... , March 3, 2015 ... with tools for implementing competency-based training to comply with ... DirectCourse is offering a new crosswalk tool ... (HCBS) implement competency-based training for direct service workers as ... & Medicaid Services (CMS) regulations. CMS amended ...
Breaking Biology Technology:Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3
... Aug. 10, 2011 Genesis Biopharma, Inc. (OTC/BB: ... today announced it has signed a Cooperative Research ... Institute (NCI).  Under the terms of the five-year ... work with Steven A. Rosenberg, M.D., Ph.D., the ...
... Accuray Incorporated (Nasdaq: ARAY ), the premier ... to present at the Wedbush Life Sciences: Management Access Conference ... a.m. ET/6:10 a.m. PT. A live webcast of ... page of the Company,s Web site at http://www.accuray.com . ...
... YORK, Aug. 9, 2011 Reportlinker.com ... report is available in its catalogue: ... Market: Facilities, Test Volumes, and Sales ... http://www.reportlinker.com/p0591318/Global-Microbiology-Testing-Market-Facilities-Test-Volumes-and-Sales-Forecasts-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic This ...
Cached Biology Technology:Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 3Global Microbiology Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country 2
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying to ... and potential for genomic science as a means to ... prevention and treatment.  I was honored to participate in ... precision medicine program. Since the 1980s ... of genomics—from the first sequenced genome of a free ...
(Date:1/22/2015)... FindBiometrics, the leading source of biometrics industry news, interviews and ... "When we launched FindBiometrics 12 years ago the ... founder and CEO of FindBiometrics. "Now it,s maturing very quickly. ... players on a very broad scale.  We are known for ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... from the atmosphere are unlikely to offer an economically feasible ... to a report issued by the American Physical Society and ... not kid ourselves that we can pour all the carbon ... it out later at little cost," said Socolow, a professor ...
... scientists have discovered how two closely related proteins guide ... and repelling these axons as they navigate the most ... make remarkably precise connections. The discovery, reported April ... proteins belonging to the "semaphorin" family of guidance cues ...
... of Botany (KIB), part of the Chinese Academy of ... Natural Products and Bioprospecting (NPAB). As a ... in the SpringerOpen portfolio, available on www.springerlink.com . ... Science (CLoS), a collection comprising more than 90 English-language ...
Cached Biology News:Report: Direct removal of carbon dioxide from air likely not viable 2Johns Hopkins scientists reveal nerve cells' navigation system 2Johns Hopkins scientists reveal nerve cells' navigation system 3New SpringerOpen journal from the Chinese Academy of Sciences 2
... peptide derived from the internal region of ... Specific for the internal region of the ... the target band at ~590 kDa. ... media from primary tracheobranchial epithelial cultures and ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Request Info...
Biology Products: